<DOC>
	<DOC>NCT00264628</DOC>
	<brief_summary>The purpose of the study is to investigate safety, tolerability and efficacy of oral GW679769 up to 120 mg dose compared to placebo in patients with ACR(American College of Rheumatology)-defined fibromyalgia, co-morbid with depression.</brief_summary>
	<brief_title>GW679769 In Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Casopitant</mesh_term>
	<criteria>Inclusion criteria: Diagnosis of fibromyalgia (ACR criteria). Nonsevere depression (HAMD score &gt;14 &lt;24). Women must commit to consistent use of an acceptable method of birth control. Exclusion criteria: Severe depression (HAMD score &gt; 24). Unable to discontinue medications for pain or depression. Laboratory and ECG value at screening outside sponsor defined ranges. Positive to stool occult blood test.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>NK1-antagonist</keyword>
	<keyword>Depression</keyword>
	<keyword>Fibromyalgia</keyword>
	<keyword>GW679769</keyword>
	<keyword>Outpatient</keyword>
</DOC>